AT 1 receptor blockers - Cost-effectiveness within the South African context

South African Medical Journal

Volumn 90, Issue 5 I, 2000, Pages 494-498

  Anderson, A Nixon ^a   Wessels, François ^b   Moodley, Indres ^c   Kropman, Keith ^a  

^a Anderson Kropman cc   (South Africa)

^b Outcomes Consultants cc   (South Africa)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CANDESARTAN; CANDESARTAN HEXETIL; IRBESARTAN; LOSARTAN; LOSARTAN POTASSIUM; VALSARTAN; ANGIOTENSIN RECEPTOR; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; ECONOMIC EVALUATION; HUMAN; HYPERTENSION; MEDICAL LITERATURE; MORTALITY; PRIVATE PRACTICE; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DRUG ANTAGONISM; ECONOMICS; META ANALYSIS; PHARMACOECONOMICS; SENSITIVITY AND SPECIFICITY; SOUTH AFRICA;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; COST-BENEFIT ANALYSIS; ECONOMICS, PHARMACEUTICAL; HUMANS; HYPERTENSION; META-ANALYSIS; RECEPTORS, ANGIOTENSIN; SENSITIVITY AND SPECIFICITY; SOUTH AFRICA;

EID: 0033623813     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Health Systems Trust and the Henry J Kaiser Family Foundation. South African Health Review 1996. 1st ed. Durban: Fishwick Printers, 1996.
2. Health Systems Trust. South African Health Review 1997. 1st ed. Durban: Kwik Kopy Printing, 1997.
3. Snyman JR, ed. MLMS Medical Specialities. Pretoria: Times Media, 1998; 38: 85-86.
4. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods far the Economic Evaluation of Health Care Programmes. 2nd ed. Oxford: Oxford University Press, 1997.
5. Timmermans PB, Wong PC, Chiu AT, et al,. Angiotensin II receptors and angiotensin II receptors antagonists. Pharmacol Rev 1993; 45: 205-251.
6. Goodfriend TL, Elliot ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med 1996; 334: 1649-1654.
7. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure. Evaluation of Losartan in the Elderly (ELITE) Study. Lancet 1997; 349: 749-752.
8. Snyman JR, ed. MIMS Desk Reference. Pretoria: Times Media, 1998; 33: 737-741.
9. Snyman JR, ed. MIMS Desk Reference. Pretoria: Times Media, 1998; 33: 850-854.
10. Elmfeldt D, George M, Hübner R, Olofsson B. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect. J Hum Hypertens 1997; 11: suppl. 2, S49-S53.
11. Reif M, White WB, Fagan TC, et al. Effects of candesartan cilexetil in patients with systemic hypertension. Am J Cardiol 1998; 82: 961-965.
12. Philipp T, Letzel H, Arens H-J. Dose-finding study of candesartan cilexetil plus hydrochlorothiazide in patients with mild to moderate hypertension. J Hum Hypertens 1997; 11: suppl. 2, S67-S68.
13. Andersson OK, Neldam S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Press 1998; 7: 53-69.
14. Ruilope LM, Simpson RL, Toh J, Arcuri KE, Goldberg AI, Sweet CS. Controlled trial of losartan given concomitantly with different doses of hydrochlorothiazide in hypertensive patients. Blood Press 1996; 5: 32-40.
15. Gavras HP, Salerno CM. The angiotensin II type 1 receptor blocker losartan in clinical practice: a review. Clin Ther 1996; 18: 1058-1067.
16. MacKay JH, Arcuri KE, Goldberg AI, Snapinn SM, Sweet CS. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. Arch Intern Med 1996; 156: 278-285.
17. Goa KL, Wagstaff AJ. Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs 1996; 51: 820-845.
18. Dahlöf B, Keller SE, Makris L, Goldberg AI, Sweet CS, Lim NY Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. Am J Hypertens 1995; 8: 578-583.
19. Tikkanen I, Omvik P, Jensen HÆ, for the Scandinavian Study Group. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertens 1995; 13: 1343-1351.
20. Benz J, Oshrain C, Henry D, Avery C, Chiang Y-T, Gatlin M. Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol 1997; 37: 101-107.